SA
SCRCQ

ScripsAmerica, Inc. operates in the healthcare sector, focusing on pharmaceutical distribution and supply chain management. The company differentiates itself through its high gross margin of 89.4% and a unique model that leverages technology to streamline pharmaceutical logistics, primarily targeting underserved markets in the U.S.

HealthcareMedical - Pharmaceuticalslow - The company has high fixed costs associated with technology infrastructure and logistics, which limits its ability to scale efficiently in response to revenue growth.

Business Overview

01Pharmaceutical distribution - 100%

ScripsAmerica generates revenue primarily through the distribution of pharmaceuticals, leveraging a technology-driven platform to optimize supply chain efficiency. The company benefits from high gross margins due to its focus on niche markets and strategic partnerships with manufacturers, allowing for competitive pricing and reduced operational costs.

What Moves the Stock

Changes in regulatory environment affecting pharmaceutical distribution

Partnerships or contracts with major healthcare providers

Market demand for specialty pharmaceuticals

Technological advancements in supply chain management

Watch on Earnings
Gross margin percentageRevenue growth rateNet income growth

Risk Factors

Regulatory changes that could impact pharmaceutical pricing and distribution

Technological disruption from competitors adopting more advanced logistics solutions

Increased competition from larger pharmaceutical distributors with more resources

Potential market entry by tech-driven startups focusing on pharmaceutical logistics

Negative equity position due to accumulated losses

Liquidity risks given the current ratio of 0.67

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The company's performance is somewhat tied to overall healthcare spending, which can be influenced by GDP growth and consumer spending on health-related products.

Interest Rates

Interest rates affect ScripsAmerica primarily through the cost of financing for operational expansions and technology investments. Higher rates could increase borrowing costs, impacting profitability.

Credit

minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on debt financing.

Live Conditions
Dow Jones FuturesS&P 500 FuturesRussell 2000 Futures

Profile

growth - Investors may be attracted by the company's high revenue growth rate and potential for market expansion in the pharmaceutical sector.

high - Given the company's operational challenges and market dynamics, it may experience significant stock price volatility.

Key Metrics to Watch
Pharmaceutical pricing trends
Regulatory changes impacting the healthcare sector
Market share in specialty pharmaceuticals
Technological adoption rates in supply chain management
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.